Induction of Cell Cycle Entry Eliminates Human Leukemia Stem Cells in a Mouse Model of AML

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2010 Feb 18

PMID 20160717

Citations 195

Authors

Yoriko Saito

Naoyuki Uchida

Satoshi Tanaka

Nahoko Suzuki

Mariko Tomizawa-Murasawa

Akiko Sone

Yuho Najima

Shinsuke Takagi

Yuki Aoki

Atsushi Wake

Shuichi Taniguchi

Leonard D Shultz

Fumihiko Ishikawa

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells have been proposed to be important for initiation, maintenance and recurrence of various malignancies, including acute myeloid leukemia (AML). We have previously reported that CD34+CD38- human primary AML stem cells residing in the endosteal region of the bone marrow are relatively chemotherapy resistant. Using a NOD/SCID/IL2rgamma(null) mouse model of human AML, we now show that the AML stem cells in the endosteal region are cell cycle quiescent and that these stem cells can be induced to enter the cell cycle by treatment with granulocyte colony-stimulating factor (G-CSF). In combination with cell cycle-dependent chemotherapy, G-CSF treatment significantly enhances induction of apoptosis and elimination of human primary AML stem cells in vivo. The combination therapy leads to significantly increased survival of secondary recipients after transplantation of leukemia cells compared with chemotherapy alone.

Citing Articles

G-CSF-combined conditioning in allogeneic transplantation for non-remission acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2).

Oda Y, Kato S, Monna-Oiwa M, Andoh S, Nannya Y, Takahashi S Blood Cell Ther. 2025; 8(1):181-185.

PMID: 40061178 PMC: 11883520. DOI: 10.31547/bct-2024-035.

The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia Development.

Sturgeon C, Wagenblast E, Izzo F, Papapetrou E Blood Cancer Discov. 2024; 6(2):94-109.

PMID: 39652739 PMC: 11876951. DOI: 10.1158/2643-3230.BCD-24-0235.

Identification of the MRTFA/SRF pathway as a critical regulator of quiescence in cancer.

Panesso-Gomez S, Cole A, Wield A, Anyaeche V, Shah J, Jiang Q bioRxiv. 2024; .

PMID: 39605642 PMC: 11601311. DOI: 10.1101/2024.11.15.623825.

SOX10 mediates glioblastoma cell-state plasticity.

Man K, Wu Y, Gao Z, Spreng A, Keding J, Mangei J EMBO Rep. 2024; 25(11):5113-5140.

PMID: 39285246 PMC: 11549307. DOI: 10.1038/s44319-024-00258-8.

Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical....

Najima Y, Maeda T, Kamiyama Y, Nakao S, Ozaki Y, Nishio H Int J Clin Oncol. 2024; 29(7):899-910.

PMID: 38755516 DOI: 10.1007/s10147-023-02461-4.

References

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T . Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med. 2009; 15(6):696-700. DOI: 10.1038/nm.1973. View

Essers M, Offner S, Blanco-Bose W, Waibler Z, Kalinke U, Duchosal M . IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009; 458(7240):904-8. DOI: 10.1038/nature07815. View

Estey E, Dohner H . Acute myeloid leukaemia. Lancet. 2006; 368(9550):1894-907. DOI: 10.1016/S0140-6736(06)69780-8. View

Dick J . Stem cell concepts renew cancer research. Blood. 2008; 112(13):4793-807. DOI: 10.1182/blood-2008-08-077941. View

Jin L, Lee E, Ramshaw H, Busfield S, Peoppl A, Wilkinson L . Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; 5(1):31-42. DOI: 10.1016/j.stem.2009.04.018. View

Clarke M, Dick J, Dirks P, Eaves C, Jamieson C, Jones D . Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66(19):9339-44. DOI: 10.1158/0008-5472.CAN-06-3126. View

Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S . Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007; 25(11):1315-21. DOI: 10.1038/nbt1350. View

Majeti R, Chao M, Alizadeh A, Pang W, Jaiswal S, Gibbs Jr K . CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138(2):286-99. PMC: 2726837. DOI: 10.1016/j.cell.2009.05.045. View

10.

Christopher M, Liu F, Hilton M, Long F, Link D . Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood. 2009; 114(7):1331-9. PMC: 2727413. DOI: 10.1182/blood-2008-10-184754. View

11.

Jorgensen H, Copland M, Allan E, Jiang X, Eaves A, Eaves C . Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res. 2006; 12(2):626-33. DOI: 10.1158/1078-0432.CCR-05-0429. View

12.

Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P . Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003; 349(8):743-52. DOI: 10.1056/NEJMoa025406. View

13.

Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T . A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood. 1994; 83(8):2086-92. View

14.

Buchner T, Berdel W, Hiddemann W . Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia. N Engl J Med. 2004; 350(21):2215-6. DOI: 10.1056/NEJM200405203502124. View

15.

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

16.

Te Boekhorst P, Lowenberg B, Vlastuin M, Sonneveld P . Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia. 1993; 7(8):1191-8. View

17.

Sipkins D, Wei X, Wu J, Runnels J, Cote D, Means T . In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005; 435(7044):969-73. PMC: 2570168. DOI: 10.1038/nature03703. View

18.

Wilson A, Laurenti E, Oser G, van der Wath R, Blanco-Bose W, Jaworski M . Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008; 135(6):1118-29. DOI: 10.1016/j.cell.2008.10.048. View

19.

Milligan D, Wheatley K, Littlewood T, Craig J, Burnett A . Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006; 107(12):4614-22. DOI: 10.1182/blood-2005-10-4202. View

20.

Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A . Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003; 9(9):1158-65. DOI: 10.1038/nm909. View